PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of PepGen, Inc. (NASDAQ:PEPG) have been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $11.50.

A number of equities research analysts recently issued reports on the company. Craig Hallum initiated coverage on PepGen in a research note on Tuesday, June 16th. They issued a “buy” rating and a $11.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research report on Thursday, May 21st. Wedbush reduced their target price on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings lowered shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. Finally, Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th.

PepGen Price Performance

Shares of PEPG opened at $1.76 on Friday. The firm has a market cap of $121.74 million, a PE ratio of -1.01 and a beta of 1.88. The stock’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $3.79. PepGen has a 1 year low of $1.01 and a 1 year high of $7.80.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. Sell-side analysts anticipate that PepGen will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PepGen

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its position in shares of PepGen by 94.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock worth $73,000 after acquiring an additional 5,453 shares in the last quarter. Heights Capital Management Inc. purchased a new position in shares of PepGen in the third quarter valued at $46,000. Burkehill Global Management LP purchased a new position in shares of PepGen in the third quarter valued at $46,000. Jefferies Financial Group Inc. bought a new stake in shares of PepGen during the 4th quarter valued at $89,000. Finally, Militia Capital Partners LP bought a new stake in shares of PepGen during the 3rd quarter valued at $72,000. Institutional investors own 58.01% of the company’s stock.

About PepGen

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).